Kazia Therapeutics Limite... (KZIA)
1.51
-0.02 (-1.31%)
At close: Jan 15, 2025, 10:16 AM
Company Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.
Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma.
It is also developing EVT801, an investigational new drug for various forms of cancer.
The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited
| Country | AU |
| IPO Date | Jan 6, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. John Edwin Friend II, M.D. |
Contact Details
Address: Three International Towers Sydney, NSW AU | |
| Website | https://www.kaziatherapeutics.com |
Stock Details
| Ticker Symbol | KZIA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001075880 |
| CUSIP Number | 48669G105 |
| ISIN Number | US48669G1058 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John Edwin Friend II, M.D. | Chief Executive Officer, MD & Director |
| Anna Sandham | Company Secretary |
| Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, Vice President of Finance & Administration and Principal Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 424B3 | Filing |
| Jan 13, 2025 | 424B3 | Filing |
| Jan 13, 2025 | 6-K | Filing |
| Jan 13, 2025 | 424B5 | Filing |
| Jan 10, 2025 | 424B5 | Filing |
| Dec 31, 2024 | 424B3 | Filing |
| Dec 31, 2024 | 424B3 | Filing |
| Dec 31, 2024 | 6-K | Filing |
| Dec 11, 2024 | 424B3 | Filing |
| Dec 11, 2024 | 424B3 | Filing |